Muraglitazar

Muraglitazar is a PPAR α/γ dual agonist for the research of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα (EC50 = 320 nM) and PPARγ (EC50 = 110 nM) [1].

Product Specifications

CAS Number

[331741-94-7]

Product Name Alternative

BMS-298585

UNSPSC

12352005

Hazard Statement

H315, H319, H335, H402

Target

PPAR

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/muraglitazar.html

Purity

98.38

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O)CN(C(OC1=CC=C(OC)C=C1)=O)CC2=CC=C(OCCC3=C(C)OC(C4=CC=CC=C4)=N3)C=C2

Molecular Formula

C29H28N2O7

Molecular Weight

516.54

Precautions

H315, H319, H335, H402

References & Citations

[1]Buse JB, Rubin CJ, Frederich R, et al. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther. 2005;27 (8) :1181-1195. |[2]Cox SL. Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia. Drugs Today (Barc) . 2005;41 (9) :579-587.